论文部分内容阅读
目的:探讨沐舒坦雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果。方法:我院治疗AECOPD患者82例,随机分为治疗组和对照组,各41例。两组患者入院后均给予AECOPD的常规对症治疗,在此基础上,治疗组患者均给予沐舒坦雾化吸入治疗,对照组患者给予α-糜蛋白酶和庆大霉素雾化吸入治疗。结果:治疗组41例患者的总有效率达97.56%,明显高于对照组的82.93%(P<0.05)。结论:沐舒坦雾化吸入治疗AECOPD可以有效缓解患者的临床症状,疗效确切,值得临床推广使用。
Objective: To investigate the clinical effect of mucosolvan inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: AECOPD patients in our hospital 82 cases were randomly divided into treatment group and control group, 41 cases each. Both groups were given conventional symptomatic treatment of AECOPD after admission. On the basis of this, the patients in the treatment group were treated with mucosolvan inhalation, while the patients in the control group were given α-chymotrypsin and gentamycin inhalation. Results: The total effective rate of the 41 patients in the treatment group was 97.56%, which was significantly higher than that in the control group (82.93%, P <0.05). Conclusion: Mucosolvan inhalation therapy for AECOPD can effectively alleviate the clinical symptoms of patients, the curative effect is exact, worthy of clinical promotion and use.